Ethylene glycol monobutyl ether


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:12571679IVR62.5 mg/L 62.5 mg/LChanges in haemocrit valuesImmunological endocrine-mediated perturbations
IVR250 mg/L 250 mg/LIncreased liver weightsHepatic endocrine-mediated perturbations
IVR250 mg/L 250 mg/LChanges in haemocrit valuesImmunological endocrine-mediated perturbations
IVR250 mg/L 250 mg/LAffects morphology of hepatocytesHepatic endocrine-mediated perturbations
IVR250 mg/L 250 mg/LHepatocellular hemangiomaEndocrine-mediated cancer;Hepatic endocrine-mediated perturbations
IVR500 mg/L 500 mg/LChanges in haemocrit valuesImmunological endocrine-mediated perturbations
IVR500 mg/L 500 mg/LIncreased liver weightsHepatic endocrine-mediated perturbations
IVR31.2 mg/L -No significant effects observed-
IVR500 mg/L 500 mg/LIncreased thymus gland weightsImmunological endocrine-mediated perturbations
IVR125 mg/L 125 mg/LChanges in adrenal gland morphologyMetabolic endocrine-mediated perturbations
IVR125 mg/L 125 mg/LChanges in haemocrit valuesImmunological endocrine-mediated perturbations
IVR125 mg/L 125 mg/LAffects morphology of hepatocytesHepatic endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.